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ABSTRACT
Treatment of HIV-1 infection with highly active antiretroviral therapy has led to sustained viral sup-
pression in the plasma in a large number of children. However, studies have suggested that the inte-
grated provirus in resting CD4+ T lymphocytes could be a source of reactivatable virus and maintain 
drug-resistant virus. We evaluated the resistance-related mutations in children receiving antiretroviral 
therapy with prolonged viral suppression. Thirty-two peripheral blood mononuclear cell samples from 
16 children with viral loads that had been below detection limits for at least 12 months were obtained 
at two different time points and the DNAs sequenced. The median CD4 cell count was 1,016 cells/
mm3 (347-2,588) and 938 cells/mm3 (440-3,038) at the fi rst and second time points, respectively. The 
median follow-up time was 15 months (9-27). Six (37.5%) and seven (43.75%) of the 16 patients 
showed at least one NRTI-associated mutation in the fi rst and second samples, respectively. Two out 
of 16 (12.5%) had an NNRTI-associated mutation at the fi rst time point and three out of 16 (18.75%) 
at the second. In addition, 14 out of 16 (87.5%) had at least one PI-associated mutation at both time 
points. Despite plasma HIV-1 RNA suppression for at least 12 months, resistance-related mutations 
from previous antiretroviral failures could still be detected in archival virus. Furthermore, viral evolu-
tion occurred at the reverse transcriptase region in spite of viral suppression to levels below 400 copies/
mL. Persistence of archival resistant virus may be relevant when considering future treatment options.
Keywords: children; HIV-1; prolonged viral suppression; antiretroviral therapy; antiretroviral resistance.
[Braz J Infect Dis 2011;15(1):60-65]©Elsevier Editora Ltda.
INTRODUCTION
Treatment of human immunodefi ciency virus 
type 1 (HIV-1)-infected individuals with high-
ly active antiretroviral therapy (HAART) has 
dramatically changed the course of the infec-
tion, reducing mortality and morbidity events 
associated with this disease.1-3 After HAART, a 
great number of patients had plasma viremia 
reduced to below the detection limits of cur-
rent sensitive assays.4-6 Antiretroviral therapy 
(ART) in children has special features, and 
consequently, results obtained from clinical 
trials in adults may not be representative of the 
results obtained when using ART in children.7,8 
Studies have shown that there is poor main-
tenance of viral load suppression in children, 
with up to half of those studied showing viral 
rebound within a year of treatment.9,10 
In patients on HAART, HIV-1 persistence is 
evidenced by free virus in the plasma; given the 
short half-life of free virus, this residual viremia 
indicates active virus production.11 However, the 
virus is able to persist as a result of several poten-
tial mechanisms, such as its ability to establish a 
state of latent infection in resting memory CD4+ 
T cells.12,13 Sensitive assays have demonstrated that 
resting memory CD4+ T cells retain replication-
competent viral DNA that may be reactivated to 
produce virus even in patients with prolonged 
suppression of plasma viremia.14 
Given the low fi delity of the HIV reverse 
transcriptase enzyme combined with the high 
replication rate of the virus, it is not surprising 
that even triple-class HAART therapy eventu-
ally fails in the vast majority of patients and is 
typically associated with the emergence of re-
sistance to viral reverse-transcriptase (RT) and 
protease (PT) inhibitors, the currently used 
antiretroviral agents.15-17 
To determine whether the integrated pro-
viruses in resting CD4+ T cells are associated 
with the development of drug-resistance muta-
tions, we studied a group of Brazilian children 
who had prolonged suppression of viral repli-
cation under ART. 
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METHODS
Patients and study design 
The study involved 32 samples of peripheral-blood mon-
onuclear cells (PBMC) from 16 children followed up 
at the Pediatric Infectious Disease Clinic (CEADIPE) at 
the Universidade Federal de São Paulo, Brazil, (UNIFESP) 
at two different time points. The first sample was col-
lected at inclusion, and the second after a minimum of 
nine months of follow-up. The inclusion criteria were 
(I) VL < 400 copies/mL with virological suppression 
(VL < 400 copies/mL) maintained for at least 12 months 
at baseline and (II) treatment with ART and only one 
viral rebound with > 1,000 copies/mL during the 12 
months prior to baseline. The parents or guardians of 
the children signed informed consent documents, and 
the study was approved by the institutional review 
board. The samples were collected from October 2002 
to March 2005. 
The children were monitored every three months, 
when they were examined physically and blood samples 
were collected for serial measurements of laboratory 
markers of HIV-1 infection, such as T-cell subsets and 
viral loads, and for safety tests. There was not a uniform 
approach to the antiretroviral treatment in the back-
ground regimen given. Instead, each pediatrician ad-
ministered the appropriate ART regimen and changed 
the drugs according to his/her interpretation of the data 
and international guidelines. Each clinician measured 
adherence by interviews with parents or guardians. 
Amplification of HIV-1 pol from proviral DNA
PCR amplification of purified proviral DNA was per-
formed as previously described.18 The cycling condi-
tions were as follows: 5 cycles of 1 min at 94°C, 1 min 
at 52°C and 1 min at 72°C, followed by 25 cycles of 
1 min at 94°C, 1 min at 55°C and 1 min at 72°C. The 
product was purified, and RT and protease regions 
were sequenced.
Genotypic analysis of HIV-1 isolates 
Genotypic HIV-1 drug resistance was determined us-
ing the Applied Biosystems ViroSeq HIV-1 Genotyp-
ing Kit. The HIV-1 protease and reverse transcriptase 
regions were analyzed using an ABI 377 sequencer and 
associated Sequence Navigator software. Drug-resist-
ance-associated mutations were defined according to 
the Stanford University HIV Drug Resistance Database 
(http://hivdb.stanford.edu) and antiretroviral resistance 
profile defined according to the Brazilian National AIDS 
guidelines for antiretroviral resistance interpretation 
(RENAGENO: http://www.aids.gov.br).
RESULTS
Population characteristics
The main characteristics of the study population at 
baseline are summarized in Table 1. The median fol-
low-up time was 15 months (9-27). Fourteen patients 
(87.5%) were on HAART at the time of the first sample, 
and two (12.5%) were receiving two NRTIs. The median 
CD4+ T-cell count was 1,016 cells/mm3 (347-2,588) and 
938 cells/mm3 (440-3,038) at the first and second time 
points, respectively. All children had HIV-1 RNA plasma 
levels below the detection limits on entry to the study 
(400 copies/mL). There were no differences in immune 
and clinical classifications for the two time points.
Resistance-associated mutation proﬁ les
Thirty-two PBMC DNA samples were extracted from the 
16 patients who had had HIV RNA levels < 400 copies/mL 
Table 1. Baseline characteristics of the study 
population
  Parameter Patients (n = 16)
  Age (years)a 11 (6 - 15)
  Male sex (%) 8 (50%)
Therapy  First time point Second time point
 2 NRTI + 1PI 10 9
 2 NRTI + 1 NNRTI 2 4
 2 NRTI + 2 PI 1 1
 2 NRTI + 2 PI  
1 1
 + 1 NNRTI
 2 NRTI 2 1
Baseline CD4   
cell count  1,016 (347-2,588) 938 (440-3,038)
(cells/mm3)  
CDCb clinical 
classification
 N 1 1
 A 3 3
 B 6 6
 C 6 6
Immune 
classification
 1 4 4
 2 6 6
 3 6 6
aMedian (range); bCenters for Disease Control and Prevention 
Classification.
Angelis, Tateno, Diaz et al.
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for at least 12 months after they started ART. Thirteen pa-
tients maintained suppression of viral replication through-
out the study. Genotypic drug resistance of all samples 
was determined by amplification and HIV-1 sequencing.
Fifteen out of the 16 individuals (93.75%) had at 
least one mutation related to decreased susceptibility to 
antiretroviral therapy. The percentage of patients with 
mutations related to drug resistance varied according to 
the drug classes used, with 31.25%, 12.5% and 31.25% 
having NRTI, NNRTI and PI-related mutations, respec-
tively, at the first time point, and 37.5%, 18.75% and 
31.25% having NRTI, NNRTI and PI-related mutations, 
respectively, at the second time point. Figures 1 and 2 
show all the mutations found for both time points for 
each reverse-transcriptase and protease region.
Two out of the 16 children (12.5%) were resistant to all 
three drug classes whereas 9/16 (56.25%) did not have any 
resistance-associated genotypic mutations at the fi rst time 
point. At the second time point, 3/16 (18.75%) were re-
sistant to all three drug classes.
According to the genotype analysis, three out of the 16 
children (18.75%) were resistant to ZDV, and 2/16 (12.5%) 
had intermediate resistance to this drug; 1/16 (6.3%) and 2/16 
(12.5%) were resistant or had intermediate resistance, respec-
tively, to ddI; 2/16 (12.5%) were resistant to 3TC and ABC; 
and 3/16 (18.75%) were resistant to d4T. A small percentage of 
children were found to have mutations conferring resistance to 
nevirapine (12.5%) and efavirenz (6.3%) at the fi rst time point.
At the second time point, four out of the 16 children 
(25%) were resistant to ZDV whereas 2/16 had intermedi-
ate resistance to this drug (12.5%); 1/16 (6.3%) and 3/16 
(18.75%) were resistant or had intermediate resistance, 
respectively, to ddI; 3/16 (18.75%) were resistant to 3TC 
and ABC; and 4/16 (25%) were resistant to d4T. Three out 
of 16 (18.75%) were found to have mutations conferring 
resistance to nevirapine.
HIV resistance profi les in children with undetectable viremia
Figure 1: Mutations found in the reverse transcriptase region at both time points.
60
50
40
30
20
10
0
60
50
40
30
20
10
0
M
4
1
L
E4
4
D
D
6
7
N
T
6
9
A
/D
K
7
0
R
A
9
8
G
K
1
0
3
N
V
1
1
8
I
M
1
8
4
V
/I
H
2
0
8
Y
R
2
1
1
K
F2
1
4
L
F2
1
5
F/
Y
F2
1
5
S
K
2
1
9
Q
Fist sample
Second sample
2 222 2
3 3 3
1
4 4
7
5
1 1 11
3
1
2
4
Figure 2: Mutations found in the protease region at both time points.
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Table 2 shows the mutations associated with decreased 
susceptibility to each antiretroviral class and the antiret-
roviral-therapy history for each patient. The major muta-
tions related to PI resistance in the fi rst sample were D30N 
(n = 2), M46I (n = 1), V82I (n = 1), I84V (n = 1) and 
L90M (n = 1), corresponding to the following rates of to-
tal resistance and intermediate resistance to the different 
drugs, respectively: RTV (12.5%; 6.3%); APV (6.3%; 0%); 
SQV (12.5%; 12.5%), IDV (6.3%; 12.5%), NFV (18.8%; 
6.3%), LPV/RTV (0%; 0%). The corresponding fi gures for 
the second sample were: D30N (n = 1), M46I (n = 0), V82I 
(n = 1), I84V (n = 0) and L90M (n = 1), corresponding 
to the following rates of total resistance and intermediate 
resistance to the different drugs, respectively: RTV (6.3%; 
0%); APV (6.3%; 0%), SQV (6.3%; 12.5%); IDV (6.3%; 
6.3%), NFV (12.5%; 6.3%), LPV/RTV (0%; 0%).
Table 2. Genotypic profiles of viral isolates and antiretroviral exposure for each patient at both time points
ID ITRN ITRNN IP  TARV*
01-1 V118DV None G16E; L24*; V32G; I47R ZDV; NVP; ddI; d4T; NFV
01-2 None None G16E ZDV; NVP; ddI; d4T; NFV
02-1 R211G None K20R; R41K; A71V; I93L ZDV; 3TC; ddI; RTV
02-2 M184V; R211G None K20R; R41K; A71V; I93L ZDV; 3TC; ddI; RTV
03-1 E44K; D67N; R211K G190K G16E; D30N; E34K; E35N; M36I;  ZDV; 3TC; d4T; RTV
   R41K; M46I; G48E; D60N; I62V
03-2 M41L; M184V;  None G16E; E35D; M36I; R41K; K45R; I62V ZDV; 3TC; d4T; RTV
 R211K; T215Y
04-1 R211K None E35D; M36I; R41K; L63S ddI; NFV; d4T; 3TC; EFV
04-2 R211K None E35D; M36I; R41K; L63S ddI; NFV; d4T; 3TC; EFV
05-1 M41L; V118IV; M184V;  A98G; L100LV;  D30N; L33F; M36L; R57K;  3TC; d4T; NFV; ddI; ZDV; EFV
 F214L; T215F K103N; V106I D60E; L63P; A71V; N88D
05-2 M41L; K70KQ; V118I; M184V;  A98G;  D30N; L33F; M36L; R41KR;  3TC; d4T; NFV; ddI; ZDV; EFV
 H208Y; F214L; T215F V106I R57K; D60E; L63P
06-1 None None None ZDV; RTV; EFV; 3TC; d4T; NFV
06-2 R211KR G190GR None ZDV; RTV; EFV; 3TC; d4T; NFV
07-1 R211X None V77I; V82I ZDV; EFV; NVP; ddI; d4T; RTV
07-2 R211K None R57K; V77I; V82I ZDV; EFV; NVP; ddI; d4T; RTV
08-1 E44DE; F214L None L63I ZDV; ddI; EFV; d4T; 3TC; NFV
08-2 F214L M230IM L63S; V77I ZDV; ddI; EFV; d4T; 3TC; NFV
09-1 V118D None L63A; T74AT ZDV; ddI; d4T; 3TC; NFV
09-2 M41L; T215S A98G L10I; L63A; T74AT; V77I ZDV; ddI; d4T; 3TC; NFV
10-1 None None E35D; I47M; G48R; L63P ZDV; ddI; EFV; d4T; 3TC
10-2 V118D None E35D; L63P ZDV; ddI; d4T; 3TC; EFV; NVP
11-1 None None M36I ZDV; ddI
11-2 None None L63H ZDV; ddI
12-1 R211K None G16E; L33V; E34K; G73S; L89M ZDV; ddI; 3TC; d4T; RTV
12-2 R211K None L33V; L89M ZDV; ddI; 3TC; d4T; RTV
13-1 M41L; M184V; T215Y None R41K; D60E; I62V; L63P ZDV; EFV; 3TC; d4T; RTV
13-2 M41L; M184V; T215Y None R41K; D60E; I62V; L63P ZDV; EFV; 3TC; d4T; RTV
14-1 D67N; T69D;  A98G L10I; E35D; M36V; R41K;  ZDV; 3TC; NFV; RTV; ddI; d4T; 
 K70R; R211K;   I62V; L63P; T74S; I84V; L90M EFV; LPV/r
14-2 D67N; T69D; K70R; H208Y;  A98G L10I; E35D; M36V; R41K;  ZDV; 3TC; NFV; RTV; ddI; 
 R211K; F214L; T215F; K219Q  I54V; I62V; L63P; T74S; L90M d4T; EFV; LPV/r
15-1 D67N; K70R; R211K None M36I; L63S ZDV; 3TC; RTV
15-2 D67N; K70R; R211K None M36I; L63S;  ZDV; 3TC; RTV
16-1 None None R41K; L63P; L90V ZDV; RTV; d4T; ddI; NFV; EFV; 
    3TC; ABC; LPV/r
16-2 None None R41K; L63P; N88D ZDV; RTV; d4T; ddI; NFV; EFV; 
   3TC; ABC; LPV/r
* Drug abbreviations: ZDV, zidovudine; 3TC, lamivudine; ddI, didanosine; d4T, stavudine; NVP, nevirapine; EFV, efavirenz; 
RTV, ritonavir; NFV, nelfinavir.; LPV, lopinavir; ABC, abacavir. The patients’ regimens at the time the study was carried out 
including the drugs listed in boldface, italic type.
Jan-1_2011.indd   63 17/2/2011   13:15:01
64
DISCUSSION
Although HIV-RNA viral loads reach undetectable levels 
less frequently in HIV-infected children than they do in 
adults,19,20 we describe a selected group of children on ART 
who experienced long-term viral suppression. Several fi nd-
ings in the present study confi rm that resistance can develop 
when the viremia level is below 400 copies/mL.
When Cohen Stuart et al.21 evaluated plasma samples 
with an average viral load of 76 copies/mL, they found 
that 72.7% of the viruses had resistance mutations to one 
or more drugs. However, when De la Rosa et al.1 studied 
adults’ PBMC with viremia levels < 50 copies/mL, they 
found that only 40% of viruses had one or more mutations 
related to resistance.
Our analysis showed a high frequency of viruses (94%) 
with resistance-related mutations at both time points, with 
percentages varying according to the drug class. At the time 
the fi rst samples were collected, there was a signifi cantly 
higher percentage of viruses with mutations selected by 
NRTIs and PIs (31.3%) than of viruses with mutations select-
ed by NNRTIs (12.5%). At the time the second samples were 
collected, 37.5% and 31.3% of the viruses were observed to 
have mutations selected by NRTIs and PIs, respectively, while 
the corresponding fi gure for NNRTIs was 18.8%.
Naeger LK and Struble KA22 showed that lopinavir/rito-
navir response rates were less than 30% when protease sub-
stitutions at M46, I54 or I84 were present at baseline. Two 
patients (ID 03 and 14) in the present study continued to 
have undetectable viral loads even in the presence of these 
mutations. However, the majority of sequences obtained 
from the latent reservoir showed a virus with mutations 
conferring resistance to drugs that were part of failed prior 
regimens. A striking result was the fact that this “archival” 
drug-resistant virus persisted despite continued treatment 
with the relevant drug with no viral replication.
In one patient (ID 14) who had previously been exposed 
to several therapeutic regimens containing ZDV, 3TC, NFV 
and RTV, the viral load fi rst reached undetectable levels in 
October 2001 while the patient was undergoing the eighth 
therapeutic regimen, which contained d4T, ddI, EFV and 
LPV/r. Although the genotypic profi le showed mutations as-
sociated with resistance to the three classes of drugs and sen-
sitivity only to LPV/r, this patient continued to have complete 
viral suppression (< 400 copies/mL) at the time the study was 
completed. The probable explanation for this is related to a 
reduction in viral fi tness due to mutations.23 A similar fi nding 
was described by Ghosn et al.24 in two patients with a virus 
that was resistant to at least two of the three drug classes in 
use, one of whom maintained complete viral suppression for 
24 months and the other for 48 months.
Another critical issue relates to two children who used 
the fi rst antiretroviral therapy (ID 11 and 15). Although 
maintaining undetectable viral loads, one of them had mu-
tations selected by a nucleoside analogue and had the same 
profi le in the two samples, while the other showed no rel-
evant changes.
It is important to emphasize that three out of the six 
children who showed non-nucleoside related mutations 
(IDs 05, 06 and 14) were receiving HAART containing this 
class of drug. With regard to the other three, one of them 
(ID 08) had been exposed to EFV in a prior regimen, and 
the other two (IDs 03 and 09) had never been exposed to an 
NNRTI before.
To summarize, we observed that 62.5% of the patients 
(10/16) had no relevant changes in the genotypic profi le 
at the RT region. In 83.3% (5/6), new substitutions could 
be found at the second time point. These were all related 
to resistance (codons 41, 98, 184, 208 and 215), suggesting 
viral evolution. Some mutations found at the fi rst time point 
were not present at the second time point (codons 44, 67 
and 103). In the PR region, we observed that 37.5% of the 
patients (6/16) had no relevant changes in the genotypic 
profi le. In 30% (3/10), new substitutions could be found in 
the second sample, all related to polymorphisms. The D30N 
mutation found in the fi rst sample (ID 03) was not present 
in the second sample.
Despite our success in controlling viral replication, sev-
eral children had mutant strains present in the lymphocytes, 
although this did not reﬂ ect any clinical or immunological 
deterioration. However, the persistence of the archival re-
sistant virus may be relevant when considering future treat-
ment options. 
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